FibroGen, Inc.
FGEN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
FibroGen, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics to treat unmet medical needs. The company's primary focus is on the development of roxadustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibi...Show More
Better Health for All
0
No relevant evidence was found in the provided articles to assess FibroGen, Inc. against the 'Better Health for All' ethical value. Both articles resulted in 404 errors, rendering their content unavailable for analysis.
1
Fair Money & Economic Opportunity
0
No evidence available to assess FibroGen, Inc on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess FibroGen, Inc on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess FibroGen, Inc on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-50
FibroGen faces significant challenges regarding honest and fair business practices. The company received an SEC subpoena in Q4 2021 related to clinical trial data for roxadustat
1
, and a derivative litigation resulted in a $28.5 million settlement
2
. These issues raise concerns about data integrity and transparency. While FibroGen emphasizes compliance, including annual training on anti-bribery policies and a whistleblower hotline
3
, the severity of the data integrity issues warrants a negative score. The company's ESG initiatives and board diversity
4
are positive, but do not outweigh the concerns raised by the SEC subpoena and settlement. The Delaware Court dismissed claims due to insufficient evidence of bad faith by directors
5
, but the underlying issues remain relevant. The company has a Speak-Up policy and whistleblower hotline
6
, but the effectiveness of these measures is unclear given the past issues. The 2023 ESG assessment indicated progress
7
, but lacks quantitative data on key ethical metrics. Given these factors, a score of -50 reflects the compliance fines and data integrity concerns.
Kind to Animals
0
No specific, concrete evidence was found in the provided articles regarding FibroGen, Inc.'s performance across any of the 'Kind to Animals' KPIs. The articles either contained general industry information not attributable to FibroGen or discussed human clinical trials without mentioning animal welfare practices or policies specific to the company.
No War, No Weapons
0
No specific, concrete evidence was found in the provided articles to assess FibroGen, Inc. against any of the 'No War, No Weapons' KPIs. The articles either pertain to other companies, are inaccessible, or describe company policies without providing measurable outcomes, quantitative data, or specific actions related to arms, defense, dual-use technologies, sanctions, peacebuilding, or conflict-related supply chain practices for FibroGen, Inc.
1
Planet-Friendly Business
0
The provided articles outline FibroGen's commitment to ESG principles, including environmental health and safety, and state that the company aims to reduce its environmental footprint through recycling, waste reduction, and the use of environmentally friendly supplies.
1
They also adhere to California environmental standards.
2
However, the articles explicitly state a lack of specific quantitative data for all requested environmental metrics, such as scope 1, 2, and 3 emissions, renewable energy percentage, water use, and waste diversion rates.
3
No information is provided regarding science-based targets, green building certifications, capital expenditure alignment with EU taxonomy, lifecycle impact assessments, recycled material ratios, carbon offsets, climate-positive initiatives, supply chain climate transparency, biodiversity efforts, or climate risk disclosures.
4
The articles also state that there are no *reported* regulatory actions, violations, or fines, which indicates an absence of reporting rather than a specific quantitative count of zero violations.
5
Respect for Cultures & Communities
0
No evidence available to assess FibroGen, Inc on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess FibroGen, Inc on Safe & Smart Tech.
Zero Waste & Sustainable Products
-50
FibroGen has implemented four waste reduction initiatives, which include recycling or donating electronic equipment, providing organic compost services, using environmentally preferred supplies, and reducing paper waste.
1
The company also works with collaboration partners to reduce product packaging and consolidate waste through good shipping practices.
2
For hazardous waste, FibroGen adheres to California environmental, health, and safety standards and city ordinances, and reports from city inspections are shared with management for appropriate corrective actions.
3